Retrospective analysis of the efficacy of adjuvant CIK cell therapy in epithelial ovarian cancer patients who received postoperative chemotherapy

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65:5–29. doi:10.3322/caac.21254.
   PubMed Web of Science ®Google Scholar
• Cho KR, Shih I. Ovarian cancer. Annu Rev Pathol. 2009;4:287–313. doi:10.1146/annurev.pathol.4.110807.092246.
   PubMed Web of Science ®Google Scholar
• Ozols RF, Bundy BN, Greer BE, Fowler JM, Clarke-Pearson D, Burger RA, Mannel RS, DeGeest K, Hartenbach E, MBaergen R. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–3200. doi:10.1200/JCO.2003.02.153.
   PubMed Web of Science ®Google Scholar
• Pfisterer J, Weber B, Reuss A, Kimmig R, Du Bois A, Wagner U, Bourgeois H, Meier W, Costa S, Blohmer JU, et al. Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECO. J Natl Cancer Inst. 2006;98:1036–1045. doi:10.1093/jnci/djj296.
   PubMed Web of Science ®Google Scholar
• Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin. 2011;61:183–203. doi:10.3322/caac.20113.
   PubMed Web of Science ®Google Scholar
• Giraudo L, Gammaitoni L, Cangemi M, Rotolo R, Aglietta M, Sangiolo D. Cytokine-induced killer cells as immunotherapy for solid tumors: current evidence and perspectives. Immunotherapy. 2015;7:999–1010. doi:10.2217/imt.15.61.
   PubMed Web of Science ®Google Scholar
• Introna M. CIK as therapeutic agents against tumors. J Autoimmun. 2017;85:32–44. doi:10.1016/j.jaut.2017.06.008.
   PubMed Web of Science ®Google Scholar
• Odunsi K. Immunotherapy in ovarian cancer. Ann Oncol. 2017;28:i1–i7. doi:10.1093/annonc/mdx444.
   Google Scholar
• Schmidt-Wolf IG, Negrin RS, Kiem HP, Blume KG, Weissman IL. Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity. J Exp Med. 1991;174:139–149.
   PubMed Web of Science ®Google Scholar
• Lu PH, Negrin RS. A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol. 1994;153:1687–1696.
   PubMed Web of Science ®Google Scholar
• Introna M, Borleri G, Conti E, Franceschetti M, Barbui AM, Broady R, Dander E, Gaipa G, D'Amico G, Biagi E, et al. Repeated infusions of donor-derived cytokine-induced killer cells in patients relapsing after allogeneic stem cell transplantation: a phase I study. Haematologica. 2007;92:952–959.
   PubMed Web of Science ®Google Scholar
• Rettinger E, Huenecke S, Bonig H, Merker M, Jarisch A, Soerensen J, Willasch A, Bug G, Schulz AK, lingebiel T, et al. Interleukin-15-activated cytokine-induced killer cells may sustain remission in leukemia patients after allogeneic stem cell transplantation: feasibility, safety and first insights on efficacy. Haematologica. 2016;101:e153–e156. doi:10.3324/haematol.2015.138016.
   PubMed Web of Science ®Google Scholar
• Boeck CL, Amberger DC, Doraneh-Gard F, Sutanto W, Guenther T, Schmohl J, Schuster F, Salih H, Babor F, Borkhardt A, et al. Significance of frequencies, compositions, and/or antileukemic activity of (DC-stimulated) Invariant NKT, NK and CIK cells on the outcome of patients with AML, ALL and CLL. J Immunother. 2017;40:224–248. doi:10.1097/CJI.0000000000000171.
   PubMed Web of Science ®Google Scholar
• Xu L, Wang J, Kim Y, Shuang ZY, Zhang YJ, Lao XM, Li YQ, Chen MS, Pawlik TM, Xia JC, et al. A randomized controlled trial on patients with or without adjuvant autologous cytokine-induced killer cells after curative resection for hepatocellular carcinoma. Oncoimmunology. 2016;5:e1083671. doi:10.1080/2162402X.2015.1083671.
   PubMed Web of Science ®Google Scholar
• Pan QZ, Tang Y, Wang QJ, Li YQ, Zhang L, Li XD, Zhao JJ, Weng DS, Liu Q, Huang LX, et al. Adjuvant cellular immunotherapy in patients with resected primary non-small cell lung cancer. Oncoimmunology. 2015;4:e1038017. doi:10.1080/2162402X.2015.1008371.
   PubMed Web of Science ®Google Scholar
• Chen CL, Pan QZ, Zhao JJ, Wang Y, Li YQ, Wang QJ, Pan K, Weng DS, Jiang SS, Tang Y, et al. PD-L1 expression as a predictive biomarker for cytokine-induced killer cell immunotherapy in patients with hepatocellular carcinoma. Oncoimmunology. 2016;5:e1176653. doi:10.1080/2162402X.2016.1176653.
   PubMed Web of Science ®Google Scholar
• Pan K, Li YQ, Wang W, Xu L, Zhang YJ, Zheng HX, Zhao JJ, Qiu HJ, Weng DS, Li JJ, et al. The efficacy of cytokine-induced killer cell infusion as an adjuvant therapy for postoperative hepatocellular carcinoma patients. Ann Surg Oncol. 2013;20:4305–4311. doi:10.1245/s10434-013-3144-x.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhu Y, Zhao E, He X, Zhao L, Wang Z, Fu X, Qi Y, Ma B, Song Y, et al. Autologous cytokine-induced killer cell immunotherapy may improve overall survival in advanced malignant melanoma patients. Immunotherapy. 2017;9:1165–1174. doi:10.2217/imt-2017-0061.
   PubMed Web of Science ®Google Scholar
• Guo Y, Han W. Cytokine-induced killer (CIK) cells: from basic research to clinical translation. Chin J Cancer. 2015;34:99–107. doi:10.1186/s40880-015-0002-1.
   PubMedGoogle Scholar
• Jiang N, Qiao G, Wang X, Morse MA, Gwin WR, Zhou L, Song Y, Zhao Y, Chen F, Zhou X, et al. Dendritic Cell/Cytokine-Induced Killer Cell Immunotherapy Combined with S-1 in Patients with Advanced Pancreatic Cancer: A Prospective Study. Clin Cancer Res. 2017;23:5066–5073. doi:10.1158/1078-0432.CCR-17-0492.
   PubMed Web of Science ®Google Scholar
• Gao X, Mi Y, Guo N, Xu H, Xu L, Gou X, Jin W. Cytokine-induced killer cells as pharmacological tools for cancer immunotherapy. Front Immunol. 2017;8:774. doi:10.3389/fimmu.2017.00774.
   PubMed Web of Science ®Google Scholar
• Lee JH, Lee JH, Lim YS, Yeon JE, Song TJ, Yu SJ, Gwak GY, Kim KM, Kim YJ, Lee JW, et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology. 2015;148:1383–1391. doi:10.1053/j.gastro.2015.02.055.
   PubMed Web of Science ®Google Scholar
• Sato E, Olson SH, Ahn J, Bundy B, Nishikawa H, Qian F, Jungbluth AA, Frosina D, Gnjatic S, Ambrosone C, et al. Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci U S A. 2005;102:18538–18543. doi:10.1073/pnas.0509182102.
   PubMed Web of Science ®Google Scholar
• Qian F, Villella J, Wallace PK, Mhawech-Fauceglia P, Tario JJ, Andrews C, Matsuzaki J, Valmori D, Ayyoub M, Frederick PJ, et al. Efficacy of levo-1-methyl tryptophan and dextro-1-methyl tryptophan in reversing indoleamine-2,3-dioxygenase-mediated arrest of T-cell proliferation in human epithelial ovarian cancer. Cancer Res. 2009;69:5498–5504. doi:10.1158/0008-5472.CAN-08-2106.
   PubMed Web of Science ®Google Scholar
• Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, Eppolito C, Qian F, Lele S, Shrikant P, et al. Tumor-infiltrating NY-ESO-1-specific CD8+ T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci U S A. 2010;107:7875–7880. doi:10.1073/pnas.1003345107.
   PubMed Web of Science ®Google Scholar
• Odunsi K, Qian F, Matsuzaki J, Mhawech-Fauceglia P, Andrews C, Hoffman EW, Pan L, Ritter G, Villella J, Thomas B, et al. Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancer. Proc Natl Acad Sci U S A. 2007;104:12837–12842. doi:10.1073/pnas.0703342104.
   PubMed Web of Science ®Google Scholar
• Huang RY, Francois A, McGray AR, Miliotto A, Odunsi K. Compensatory upregulation of PD-1, LAG-3, and CTLA-4 limits the efficacy of single-agent checkpoint blockade in metastatic ovarian cancer. Oncoimmunology. 2017;6:e1249561. doi:10.1080/2162402X.2016.1249561.
   PubMed Web of Science ®Google Scholar
• Liu J, Li H, Cao S, Zhang X, Yu J, Qi J, An X, Yu W, Ren X, Hao, X. Maintenance therapy with autologous cytokine-induced killer cells in patients with advanced epithelial ovarian cancer after first-line treatment. J Immunother. 2014;37:115–122. doi:10.1097/CJI.0000000000000021.
   PubMed Web of Science ®Google Scholar
• Santoiemma PP, Reyes C, Wang LP, McLane MW, Feldman MD, Tanyi JL, Powell DJ. Systematic evaluation of multiple immune markers reveals prognostic factors in ovarian cancer. Gynecol Oncol. 2016;143:120–127. doi:10.1016/j.ygyno.2016.07.105.
   PubMed Web of Science ®Google Scholar
• Lum C, Steer CB. Targeted therapies in the management of ovarian cancer: A focus on older patients. Drugs Aging. 2017;34:821–831. doi:10.1007/s40266-017-0495-1.
   PubMed Web of Science ®Google Scholar
• Tortorella L, Vizzielli G, Fusco D, Cho WC, Bernabei R, Scambia G, Colloca G. Ovarian cancer management in the oldest old: improving outcomes and tailoring treatments. Aging Dis. 2017;8:677–684. doi:10.14336/AD.2017.0607.
   PubMed Web of Science ®Google Scholar
• Muller L, Pawelec G. Aging and immunity - impact of behavioral intervention. Brain Behav Immun. 2014;39:8–22. doi:10.1016/j.bbi.2013.11.015.
   PubMed Web of Science ®Google Scholar
• Liu Y, Liu H, Liu H, He P, Li J, Liu X, Chen L, Wang M, Xi J, Wang H, et al. Dendritic cell-activated cytokine-induced killer cell-mediated immunotherapy is safe and effective for cancer patients >65 years old. Oncol Lett. 2016;12:5205–5210. doi:10.3892/ol.2016.5337.
   PubMed Web of Science ®Google Scholar
• Gubbels JA, Felder M, Horibata S, Belisle JA, Kapur A, Holden H, Petrie S, Migneault M, Rancourt C, Connor JP, et al. MUC16 provides immune protection by inhibiting synapse formation between NK and ovarian tumor cells. Mol Cancer. 2010;9:11. doi:10.1186/1476-4598-9-254.
   PubMed Web of Science ®Google Scholar
• Patankar MS, Jing Y, Morrison JC, Belisle JA, Lattanzio FA, Deng Y, Wong NK, Morris HR, Dell A, Clark GF. Potent suppression of natural killer cell response mediated by the ovarian tumor marker CA125. Gynecol Oncol. 2005;99:704–713. doi:10.1016/j.ygyno.2005.07.030.
   PubMed Web of Science ®Google Scholar
• Bowtell DD, Bohm S, Ahmed AA, Aspuria PJ, Bast RJ, Beral V, Berek JS, Birrer MJ, Blagden S, Bookman MA, et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat Rev Cancer. 2015;15:668–679.
   PubMed Web of Science ®Google Scholar
• Spiliotis J, Halkia E, Lianos E, Kalantzi N, Grivas A, Efstathiou E, Giassas S. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study. Ann Surg Oncol. 2015;22:1570–1575. doi:10.1245/s10434-014-4157-9.
   PubMed Web of Science ®Google Scholar
• Gadducci A, Cosio S, Zizioli V, Notaro S, Tana R, Panattoni A, Sartori E. Patterns of recurrence and clinical outcome of patients with stage IIIC to stage IV epithelial ovarian cancer in complete response after primary debulking surgery plus chemotherapy or neoadjuvant chemotherapy followed by interval debulking surgery: an italian multicenter retrospective study. Int J Gynecol Cancer. 2017;27:28–36. doi:10.1097/IGC.0000000000000843.
   PubMedGoogle Scholar
• Yang L, Du C, Wu L, Yu J, An X, Yu W, Cao S, Li H, Ren X. Cytokine-induced killer cells modulates resistance to cisplatin in the A549/DDP cell line. J Cancer. 2017;8:3287–3295. doi:10.7150/jca.19426.
   PubMed Web of Science ®Google Scholar
• Zhao Q, Zhang H, Li Y, Liu J, Hu X, Fan L. Anti-tumor effects of CIK combined with oxaliplatin in human oxaliplatin-resistant gastric cancer cells in vivo and in vitro. J Exp Clin Cancer Res. 2010;29:118. doi:10.1186/1756-9966-29-17.
   PubMed Web of Science ®Google Scholar
• Gammaitoni L, Giraudo L, Macagno M, Leuci V, Mesiano G, Rotolo R, Sassi F, Sanlorenzo M, Zaccagna A, Pisacane A, et al. Cytokine-induced killer cells kill chemo-surviving melanoma cancer stem cells. Clin Cancer Res. 2017;23:2277–2288. doi:10.1158/1078-0432.CCR-16-1524.
   PubMed Web of Science ®Google Scholar
• Linn YC, Lau SK, Liu BH, Ng LH, Yong HX, Hui KM. Characterization of the recognition and functional heterogeneity exhibited by cytokine-induced killer cell subsets against acute myeloid leukaemia target cell. Immunology. 2009;126:423–435. doi:10.1111/j.1365-2567.2008.02910.x.
   PubMed Web of Science ®Google Scholar
• Liu J, Wang L, Wang Y, Zhang W, Cao Y. Phenotypic characterization and anticancer capacity of CD8+ cytokine-induced killer cells after antigen-induced expansion. PLoS One. 2017;12:e175704.
   Web of Science ®Google Scholar
• Waugh KA, Leach SM, Slansky JE. Targeting transcriptional regulators of CD8+ T cell dysfunction to boost anti-tumor immunity. Vaccines (Basel). 2015;3:771–802. doi:10.3390/vaccines3030771.
   PubMed Web of Science ®Google Scholar
• Pievani A, Borleri G, Pende D, Moretta L, Rambaldi A, Golay J, Introna M. Dual-functional capability of CD3+CD56+ CIK cells, a T-cell subset that acquires NK function and retains TCR-mediated specific cytotoxicity. Blood. 2011;118:3301–3310. doi:10.1182/blood-2011-02-336321.
   PubMed Web of Science ®Google Scholar
• Levine AG, Mendoza A, Hemmers S, Moltedo B, Niec RE, Schizas M, Hoyos BE, Putintseva EV, Chaudhry A, Dikiy S, et al. Stability and function of regulatory T cells expressing the transcription factor T-bet. Nature. 2017;546:421–425. doi:10.1038/nature22360.
   PubMed Web of Science ®Google Scholar
• Crome SQ, Nguyen LT, Lopez-Verges S, Yang SY, Martin B, Yam JY, Johnson DJ, Nie J, Pniak M, Yen PH, et al. A distinct innate lymphoid cell population regulates tumor-associated T cells. Nat Med. 2017;23:368–375. doi:10.1038/nm.4278.
   PubMed Web of Science ®Google Scholar